本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Therapix Biosciences Ltd.

0.3170
0.0000
成交量:- -
成交额:- -
市值:181.31万
市盈率:-0.11
高:0.3170
开:0.3170
低:0.3170
收:0.3170
数据加载中...
2021/04/28

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/04/21

招股说明书

F-1 - Registration statement for certain foreign private issuers
2021/03/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/01

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/12/09

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/12/03

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2020/11/30

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/11/16

SEC问询函

CORRESP [Cover] - Correspondence
2020/11/12

SEC问询函

CORRESP [Cover] - Correspondence
2020/11/05

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2020/11/04

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2020/10/21

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2020/10/21

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2020/10/09

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2020/09/22

交易所摘牌声明

25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2020/09/08

招股说明书

F-1 - Registration statement for certain foreign private issuers
2020/08/10

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/07/01

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2020/06/26

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2020/06/15

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]